Evogene Ltd.
EVGN
$1.06
$0.010.47%
NASDAQ
| 06/30/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 146.62% | 178.72% | -53.81% | -389.91% | 708.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 146.62% | 178.72% | -53.81% | -389.91% | 708.37% |
| Cost of Revenue | -59.52% | 89.70% | 103.91% | -27.11% | 325.83% |
| Gross Profit | 133.51% | 375.56% | -78.56% | -1,256.48% | 841.04% |
| SG&A Expenses | 8.32% | -10.65% | 39.44% | -49.25% | -2.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.94% | -18.62% | -3.65% | -59.78% | 5.12% |
| Operating Income | 42.46% | 33.57% | -41.53% | 32.45% | 41.06% |
| Income Before Tax | 10.10% | 100.03% | -74.66% | 32.89% | 46.03% |
| Income Tax Expenses | -- | 275.00% | 120.00% | -- | -200.00% |
| Earnings from Continuing Operations | 10.10% | 99.93% | -74.91% | 33.05% | 46.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -61.31% | -41.30% | 567.46% | -25.03% | -120.36% |
| Net Income | 17.66% | 106.47% | -91.52% | 22.84% | 39.12% |
| EBIT | 42.46% | 33.57% | -41.53% | 32.45% | 41.06% |
| EBITDA | 47.30% | 35.76% | -62.15% | 27.25% | 45.41% |
| EPS Basic | 42.00% | 104.81% | -61.35% | 36.87% | 48.71% |
| Normalized Basic EPS | -- | 102.45% | -- | -- | 44.48% |
| EPS Diluted | 42.00% | 104.81% | -61.35% | 36.87% | 48.71% |
| Normalized Diluted EPS | -- | 102.45% | -- | -- | 44.48% |
| Average Basic Shares Outstanding | 42.05% | 34.34% | 18.70% | 22.15% | 18.70% |
| Average Diluted Shares Outstanding | 42.05% | 34.34% | 18.70% | 22.15% | 18.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |